Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Despina Barmparousi"'
Autor:
Efstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, Dimitra Gika, Charis Matsouka, Despina Barmparousi, Irini Grapsa, Erasmia Psimenou, Aristotle Bamias, Meletios Athanasios Dimopoulos
Publikováno v:
Haematologica, Vol 92, Iss 4 (2007)
The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in
Externí odkaz:
https://doaj.org/article/191a7c3c12fe49bf8c47a8503d37a8ad
Autor:
Athanasios Anagnostopoulos, Dimitra Gika, Aristotle Bamias, Erasmia Psimenou, Despina Barmparousi, Charis Matsouka, Maria Roussou, Meletios A. Dimopoulos, Irini Grapsa, Efstathios Kastritis
Publikováno v:
Haematologica. 92:546-549
The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::755d3da3533b45e73e72e2d08c5cb6c2
https://doi.org/10.3324/haematol.10759
https://doi.org/10.3324/haematol.10759
Autor:
Athanasios Anagnostopoulos, Despina Barmparousi, Meletios A. Dimopoulos, Maria Roussou, Vasiliki Koutsoukou, Efstathios Kastritis, Charis Matsouka
Publikováno v:
Leukemia & Lymphoma. 48:754-758
There are limited data regarding the long term follow up after thalidomide based regimen and the outcome of patients when they progress and they receive further treatment. We reassessed our original series of 43 patients with previously treated multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd8f7f34fb3047cae186669ca3fac76f
https://doi.org/10.1080/10428190601186168
https://doi.org/10.1080/10428190601186168
Autor:
Magdalini Migkou, Meletios A. Dimopoulos, Irini Grapsa, Despina Barmparousi, Maria Roussou, Evangelos Terpos, Charis Matsouka, Efstathios Kastritis, Erasmia Psimenou
Publikováno v:
Leukemialymphoma. 49(5)
Renal failure is a common feature of multiple myeloma and a major management problem. However there is limited data regarding the reversibility of renal failure, the kinetics of serum creatinine and the safety of novel agents such as bortezomib when
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8de3498ede565abd501b458e0ed0e27
https://pubmed.ncbi.nlm.nih.gov/18452070
https://pubmed.ncbi.nlm.nih.gov/18452070
Autor:
Despina Barmparousi, Erasmia Psimenou, Charis Matsouka, Efstathios Kastritis, Maria Roussou, Meletios A. Dimopoulos, Irini Grapsa, Flora Zagouri, Dimitrios Christoulas, Evangelos Terpos, Magdalini Migkou, Maria Gavriatopoulou
Publikováno v:
Blood. 112:1725-1725
Renal impairment (RI) is a frequent complication of multiple myeloma (MM) and a major management problem. Previous studies have shown that bortezomib is active and well tolerated in MM patients with RI and can be associated with improvement of renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96326e039ceb0f5177e0f2c294b88667
https://doi.org/10.1182/blood.v112.11.1725.1725
https://doi.org/10.1182/blood.v112.11.1725.1725
Autor:
Despina Barmparousi, Maria Roussou, Meletios A. Dimopoulos, Athanasios Anagnostopoulos, Charis Matsouka, Magdalini Migkou, Efstathios Kastritis, Evangelos Eleftherakis-Papaiakovou
Publikováno v:
Blood. 110:4812-4812
Introduction: The effectiveness of thalidomide based regimens (TBR) in patients with relapsed/refractory multiple myeloma is well established. However, there are still limited data regarding the long term follow up after such regimens and the outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be0749bb5a743908e90f8c2eef351fc3
https://doi.org/10.1182/blood.v110.11.4812.4812
https://doi.org/10.1182/blood.v110.11.4812.4812
Autor:
Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Despina Barmparousi, Erasmia Psimenou, Evangelos Terpos, Maria Roussou, Efstathios Kastritis, Irini Grapsa, Charis Matsouka
Publikováno v:
Blood. 110:2739-2739
Introduction: Renal failure is a common feature of multiple myeloma and a major management problem. There is limited data regarding the reversibility of renal failure, the kinetics of serum creatinine and the safety of novel agents, such as bortezomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a8a33779bc6d573058d0b0d4420c471
https://doi.org/10.1182/blood.v110.11.2739.2739
https://doi.org/10.1182/blood.v110.11.2739.2739
Autor:
Vangelis Eleftherakis-Papaiakovou, Charis Matsouka, Athanasios Anagnostopoulos, Despina Barmparousi, Lia A. Moulopoulos, Evangelos Terpos, Maria Roussou, Efstathios Kastritis, Meletios A. Dimopoulos
Publikováno v:
Blood. 108:5018-5018
Bone lytic disease is a major feature of multiple myeloma (MM) and is characterized by an increased osteoclast activity which is accompanied by a suppressed osteoblast function. Furthermore, increased angiogenesis is implicated in the pathogenesis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e8cae2168a9ed1f7dfe303dde9ab16
https://doi.org/10.1182/blood.v108.11.5018.5018
https://doi.org/10.1182/blood.v108.11.5018.5018
Autor:
Dimitra Gika, Aristotle Bamias, Vassiliki Koutsoukou, Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Efstathios Kastritis, Charis Matsouka, Maria Roussou, Despina Barmparousi
Publikováno v:
Blood. 108:3586-3586
Introduction: Approximately 20% of patients with multiple myeloma present with renal failure (RF). It has been reported that with supportive measures and with antimyeloma treatment RF is reversible in 25 to 58% of patients. However, the impact of spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aa7a62f1ad729f94571de3269caa32f
https://doi.org/10.1182/blood.v108.11.3586.3586
https://doi.org/10.1182/blood.v108.11.3586.3586
Autor:
Roussou, Maria1 (AUTHOR), Kastritis, Efstathios1 (AUTHOR), Migkou, Magdalini1 (AUTHOR), Psimenou, Erasmia1 (AUTHOR), Grapsa, Irini1 (AUTHOR), Matsouka, Charis1 (AUTHOR), Barmparousi, Despina1 (AUTHOR), Terpos, Evangelos2 (AUTHOR), Dimopoulos, Meletios Athanasios1 (AUTHOR) mdimop@med.uoa.gr
Publikováno v:
Leukemia & Lymphoma. May2008, Vol. 49 Issue 5, p890-895. 6p. 4 Charts, 2 Graphs.